ReCode Therapeutics maintains its corporate headquarters and primary research and development laboratories in Menlo Park, California. Situated centrally within the dense biotechnology innovation hub of the San Francisco Bay Area, the company utilizes its strategic location to attract top-tier scientific talent, collaborate with major academic medical centers, and advance its proprietary precision genetic medicines and specialized delivery platforms designed to address life-threatening respiratory and systemic genetic diseases.